cancer of unknown primary

The company said it will use the proceeds to develop new liquid biopsy tests to predict drug response in cancer patients.

The companies will combine GenomOncology's GO Immuno-Oncology Workbench analysis software with Fluidigm's Advanta IO Gene Expression Assay.

The companies will incorporate PerkinElmer's LabChip GX Touch nucleic acid analyzer in the upfront workflow of Agena's MassArray system.

A study found that cis-regulatory variation modifies the penetrance of coding variants, and that variants' regulatory haplotype configuration affects disease risk.

The China-based company said that it now has 11 products that have been CE marked, and has applied for additional CE certification for other tests.

IBM's supercomputing platform will continue to provide AI support to advanced cancer patients at VA medical centers for at least another year.

The partners will use NanoString's PanCancer panel in NCI-sponsored trials to characterize immune activity and develop potentially predictive gene signatures.

The technology behind Mammoth's platform bears a striking resemblance to the CRISPR-based SHERLOCK platform developed by researchers at the Broad Institute.

As part of a collaboration with Freenome, Institut Curie will look for correlations between circulating biomarkers and human response to cancer immunotherapies.

The latest version of the nucleic acid detection platform uses three CRISPR enzymes, making it more sensitive and capable of smaller quantitative measurements.

Pages

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.